Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
December 08, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept...
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D....
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
November 19, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET
November 12, 2020 16:01 ET
|
Orchard Therapeutics (Europe) Limited
First look at preclinical data in frontotemporal dementia with progranulin mutations (GRN-FTD) and new amyotrophic lateral sclerosis (ALS) program NOD2 mutation revealed as Crohn’s disease (CD)...
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit
November 09, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene...
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
November 05, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the presentation of new clinical data at the...
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
November 03, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Libmeldy TM Receives Positive CHMP Opinion for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD); U.S. IND Application on Track for Year End 2020 Cash and Investments of More Than $200M...
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020
November 02, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New...
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
October 22, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby...
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
October 16, 2020 06:00 ET
|
Orchard Therapeutics (Europe) Limited
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants One-time treatment with Libmeldy...